Top Markets
Coin of the day
Devonian Health Group Inc. Devonian Health Group Inc.

Devonian Health Group Inc.

DVHGF
Rank in Stocks #29818
Devonian Health Group Inc. specializes in the creation of botanical-based... Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products. Furthermore, the company has established a strategic partnership with CannTx Life Sciences Inc. to collaborate on the development of cannabinoid-based pharmaceutical drugs. Devonian Health Group Inc. was founded in 2015 and is based in Québec, Canada.
Share Price
$7.00
Last synced: 2026-08-17
Market Cap
$19.47M
Change (1 day)
0.00%
Change (1 year)
-35.19%
Country
CA
Trade Devonian Health Group Inc. (DVHGF)

Category

P/S ratio for Devonian Health Group Inc. (DVHGF)
P/S ratio as of 2026 TTM: 0
According to Devonian Health Group Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Devonian Health Group Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
- -
KR